Please login to the form below

Not currently logged in
Email:
Password:

Praluent

This page shows the latest Praluent news and features for those working in and with pharma, biotech and healthcare.

Dupixent helps put Sanofi back on growth track

Dupixent helps put Sanofi back on growth track

Meanwhile, cholesterol-lowerer Praluent (alirocumab) sales came in at 68m in the quarter – up 64% year-on-year but still way below initial expectations, largely as a result of a reluctance ... Sanofi and partner Regeneron cut the price of Praluent

Latest news

More from news
Approximately 22 fully matching, plus 29 partially matching documents found.

Latest Intelligence

  • Astellas: Ten years young Astellas: Ten years young

    Repatha from Amgen was the first in the class to be approved in Japan in January, although it will likely only be months before Sanofi's rival Praluent will join it

  • Going the distance Going the distance

    Looking to the second half of this year and Sanofi is aiming for a Q3 launch for its new PCSK9 cardiovascular disease management drug Praluent (alirocumab), which comes from its collaboration ... We are very much encouraging collaboration, so we are

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...

Infographics